JPRN-UMIN000021742Completed未知
Analysis of predictive biomarker and analysis of correlations between toxicities and SNPs that can be related to pharmacokinetics, in trifluridine/tipiracil hydrochloride therapy for previously fluoropyrimidine-treated elderly patients with unresectable or recurrent colorectal cancer - Analysis of biomarker for trifluridine/tipiracil hydrochloride therapy
Tohoku Clinical Oncology Research and Education Society (T-CORE)0 sites20 target enrollmentStarted: April 1, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 65years-old to 85years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who fulfill the following criteria for exclusion are excluded. 1) Synchronous double cancer or past history of other cancer within 5 years, except curable carcinoma in situ and skin cancer. 2) Active infection and inflammation (the body temperature with >= 38.0 degree of celsius). 3) Active hepatitis. 4) Serious complications or severe complications that require hospitalization for therapy, such as gastrointestinal paresthesia, bowel obstruction, interstitial pneumonia, pulmonary fibrosis, and uncontrollable hypertension, diabetes mellitus, renal dysfunction, liver dysfunction, and hepatic cirrhosis. 5) Chronic diarrhea (>= 4 times a day, or watery). 6) Active gastrointestinal bleeding. 7) Effusion that requires drainage. 8) Thoracotomy, laparotomy, or laparoscopic surgery within 28 days before registration. 9) Receiving medications with psychotropic drugs for mental disorders, or having mental disorders that require medications with psychotropic drugs. 10) Determined to be inappropriate to enter the study by the responsible researcher or contributing researchers, for any other reasons.
Investigators
Similar Trials
Unknown
Not Applicable
Analysis of predictive biomarker and analysis of correlations between toxicities and SNPs that can be related to pharmacokinetics, in ramucirumab plus paclitaxel therapy for elderly patients with unresectable or recurrent gastric cancerunresectable or recurrent gastric cancerJPRN-UMIN000021743Tohoku Clinical Oncology Research and Education Society (T-CORE)30
Completed
Not Applicable
A study of evaluation to the predictive biomarker of Nivolumab in peripheral blood and pleural effusion.previously treated patients with advanced non-small-cell lung cancerJPRN-UMIN000023873Respiratory Medicine, Allergy and Rheu matic Diseases Osaka University Graduate School of Medicine10
Not yet recruiting
Not Applicable
Analysis for the prediction of systemic therapies in patients with locally advanced hepatocellular carcinomaNeoplasmsKCT0004206Seoul National University Hospital400
Completed
Not Applicable
Predictive biomarker analysis for clinical outcome in cancer patients using salivary cytokinesnon-small cell lung cancer, head and neck cancer, renal cell carcinoma, gastric cancerJPRN-UMIN000029444Shinshu University110
Recruiting
Not Applicable
Exploratory analysis of biomarkers predicting the treatment response and the prognosis in patients with gastric carcinomaGastric cancerJPRN-UMIN000036886Sapporo Medical University350